Meet the 1.4% Yield Dividend Stock That Could Soar in 2026

Novo Nordisk's stock has declined over 50% in the past year, primarily due to intensified competition from Eli Lilly's Zepbound, which now leads in U.S. prescriptions, and the prevalence of compounded GLP-1 drugs, despite the company's strong financial performance. To regain market share and address competitive pressures, Novo Nordisk is developing an oral version of Wegovy (semaglutide), which showed a 16.6% weight reduction in Phase 3 trials and aims for FDA approval by year-end. This strategic move, coupled with the projected tenfold growth of the obesity drug market to $150 billion by 2035, suggests current analyst pessimism may be overblown, positioning the stock for a potential rebound as early as 2026.

Analysis

Novo Nordisk (NVO) has experienced a significant stock price decline of over 50% in the past year, despite demonstrating robust financial performance with surging revenues and profits since 2023. This underperformance is primarily driven by intensified competition, notably from Eli Lilly's Zepbound, which has surpassed Wegovy in the U.S. obesity market with 419,000 prescriptions compared to NVO's 282,000. The proliferation of compounded semaglutide versions from telehealth companies, operating under an FDA loophole, has further exacerbated market share erosion.

In response to these competitive pressures, Novo Nordisk is strategically developing an oral version of Wegovy (semaglutide), which showed a 16.6% average weight reduction in Phase 3 trials over 64 weeks. This tablet formulation, targeted for FDA approval by year-end, is expected to enhance patient appeal and production efficiency. The oral drug aims to shift users from compounded injectables and strengthen NVO's competitive stance against both branded and generic alternatives.

Despite recent analyst downgrades contributing to low investor expectations, the broader obesity drug market is projected for substantial growth, from $15 billion to $150 billion by 2035. This significant market expansion suggests that current pessimism regarding NVO's long-term growth prospects may be overblown. A successful launch of the oral Wegovy, even with anticipated competition from Eli Lilly, could re-instill investor confidence and potentially drive a stock rebound as early as 2026, given the vast market potential.

Key Decisions for Investors

• Investors should closely monitor the progress and FDA approval timeline for Novo Nordisk's oral Wegovy, as its successful launch is a critical catalyst for regaining market share and countering competitive pressures.
• Evaluate current analyst growth estimates against the projected tenfold expansion of the obesity drug market by 2035, considering potential upside if NVO effectively executes its oral drug strategy and captures a significant portion of this growth.
• Assess the evolving competitive landscape, particularly Eli Lilly's oral GLP-1 developments, but recognize that the vast and expanding obesity market may accommodate multiple major players, reducing zero-sum competition concerns.